This $1,347,118 Project Grant was awarded on May 15, 2023 by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The funding supports research conducted by the University of Miami to target KIF20A, a kinesin with a novel, non-canonical role in castration-resistant prostate cancer. The research aims to transform health care for Service Members and the American public through innovative and impactful biomedical research investigating medical solutions for the battlefield. The University of Miami, a private non-profit educational institution, will perform this 3-year research project in Miami, FL.
Generated 4/9/24, 6:10 AM